KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Assets: 2009-2025

Historic Assets for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Sep 2025 value amounting to $4.9 billion.

  • Alnylam Pharmaceuticals' Assets rose 15.38% to $4.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.9 billion, marking a year-over-year increase of 15.38%. This contributed to the annual value of $4.2 billion for FY2024, which is 10.71% up from last year.
  • According to the latest figures from Q3 2025, Alnylam Pharmaceuticals' Assets is $4.9 billion, which was up 6.26% from $4.6 billion recorded in Q2 2025.
  • In the past 5 years, Alnylam Pharmaceuticals' Assets ranged from a high of $4.9 billion in Q3 2025 and a low of $3.3 billion during Q1 2021.
  • In the last 3 years, Alnylam Pharmaceuticals' Assets had a median value of $4.0 billion in 2024 and averaged $4.0 billion.
  • In the last 5 years, Alnylam Pharmaceuticals' Assets skyrocketed by 42.80% in 2021 and then declined by 5.10% in 2022.
  • Over the past 5 years, Alnylam Pharmaceuticals' Assets (Quarterly) stood at $3.6 billion in 2021, then fell by 2.66% to $3.5 billion in 2022, then increased by 7.99% to $3.8 billion in 2023, then grew by 10.71% to $4.2 billion in 2024, then climbed by 15.38% to $4.9 billion in 2025.
  • Its Assets stands at $4.9 billion for Q3 2025, versus $4.6 billion for Q2 2025 and $4.2 billion for Q1 2025.